Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis
NCT03269773Phase 3Completed
- Sponsor
- Kangstem Biotech
- Start
- Apr 2018
- Primary completion
- Mar 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of Promostem in atopic dermatitis (AD), sponsored by Kangstem Biotech. Started Apr 2018; status: completed.
02
Drugs
Promostem
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03269773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03269773.